Cover Image
QR Code

First-Line Modified FOLFIRINOX in Metastatic Pancreatic Cancer: Real-World Outcomes and Prognostic Factors From a Vietnamese Cohort.

Background: Metastatic pancreatic cancer is an aggressive malignancy with limited survival despite intensive chemotherapy. While modified FOLFIRINOX (mFOLFIRINOX) has illustrated efficacy, its real-world data are limited in low-resource healthcare systems. This study evaluated efficacy and toxicity...

Full description

Published in:Clinical Medicine Insights: Oncology Vol. 20; pp. 1 - 9
Main Authors: Nguyen, Huy Van, Dinh, Phuong Thi, Tran, Thang, Hoang, Cuc Thi
Format: research tables/charts Journal Article
Published: Sage Publications Inc. 2/25/2026
Online Access:View this record in EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=191984260&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 191984260
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        11795549
        B3KT
      jtl: Clinical Medicine Insights: Oncology
      issn: 11795549
      maglogo: Y
    pubinfo:
      dt: 2/25/2026
      vid: 20
      pid: 344
      pub: Sage Publications Inc.
      place: Thousand Oaks, California
    artinfo:
      ui:
        191984260
        191984260
        191984260
        10.1177/11795549261426101
        191984260
      ppf: 1
      ppct: 8
      formats:
        fmt:
          – @attributes:
              type: T
          – @attributes:
              type: P
      tig:
        atl: First-Line Modified FOLFIRINOX in Metastatic Pancreatic Cancer: Real-World Outcomes and Prognostic Factors From a Vietnamese Cohort.
      aug:
        au:
          Nguyen, Huy Van
          Dinh, Phuong Thi
          Tran, Thang
          Hoang, Cuc Thi
        affil: Department of Medical Oncology, National Cancer Hospital, Hanoi, Vietnam
      sug:
        subj:
          Pancreatic Neoplasms Prognosis
          Pancreatic Neoplasms Drug Therapy
          Neoplasm Metastasis Drug Therapy
          Antineoplastic Agents, Combined Administration and Dosage
          Antineoplastic Agents, Combined Therapeutic Use
          Vietnamese Persons Psychosocial Factors
          Drug Toxicity
          Drug Efficacy
          Human
          Male
          Female
          Adult
          Middle Age
          Aged
          Retrospective Design
          Prospective Studies
          Record Review
          Vietnam
          Cancer Care Facilities Vietnam
          Guideline Adherence
          Kaplan-Meier Estimator
          Overall Survival
          Progression-Free Survival
          Log-Rank Test
          Cox Proportional Hazards Model
          Regression
          Confidence Intervals
          Multivariate Analysis
          Descriptive Statistics
          Univariate Statistics
          Data Analysis Software
          Cancer Patients Psychosocial Factors
          Adult: 19-44 years
          Middle Aged: 45-64 years
          Aged: 65+ years
          Male
          Female
      ab: Background: Metastatic pancreatic cancer is an aggressive malignancy with limited survival despite intensive chemotherapy. While modified FOLFIRINOX (mFOLFIRINOX) has illustrated efficacy, its real-world data are limited in low-resource healthcare systems. This study evaluated efficacy and toxicity and identified prognostic factors of mFOLFIRINOX as a first-line therapy for Vietnamese patients with metastatic pancreatic cancer. Methods: We conducted a retrospective cohort study of 36 patients receiving mFOLFIRINOX as first-line therapy. All patients received peg-filgrastim as the primary prophylaxis. An application of flexible treatment approach—interruption was permitted between cycles under physician guidance. Progression-free survival (PFS), overall survival (OS), tumor response, and adverse events were assessed. Prognostic factors were analyzed using log-rank tests and Cox regression models. Results: The median follow-up was 15.6 months (95% confidence interval [CI] 3.8-27.3). The overall response rate (ORR) was 30.6 %, and the disease control rate (DCR) was 66.6%. The median progression-free survival was 6.7 (95% CI 5.4-8) months, and the median overall survival was 12.5 (95% CI 9.5-15.4) months. Grade 3 or 4 toxicities were mainly hematologic, including neutropenia in 33.4%, and anemia in 5.6% of patients. No cases of febrile neutropenia were observed. Univariate analyses identified performance status (PS) and age under 60 years as associated with improved outcomes. In multivariate Cox regression, PS remained an independent prognostic factor for overall survival. Conclusion: mFOLFIRINOX regimen demonstrated efficacy and manageable toxicity in Vietnamese patients with metastatic pancreatic cancer. An individualized approach involving treatment interruptions was observed in patients with relatively favorable outcomes. These findings support the feasibility of the regimen in real-world settings.
      pubtype: Academic Journal
      doctype:
        research
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N